FDA pushes back decision date for Acorda’s Parkinson’s drug

Acorda Therapeutics (NSDQ:ACOR) said today that the FDA pushed back its goal date for the agency’s review of Acorda’s inhaled levodopa Parkinson’s therapy.

The FDA’s date to make a decision about Acorda’s Inbrija product was moved from Oct. 5, 2018 to Jan. 5, 2019. The Ardsley, N.Y.-based company said the extension is related to submissions it made in response to requests from the FDA for additional data on chemistry, manufacturing & controls.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA pushes back decision date for Acorda’s Parkinson’s drug appeared first on MassDevice.

from MassDevice https://ift.tt/2NEx9lD